Compare NAZ & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NAZ | SGMT |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 169.4M |
| IPO Year | 1995 | 2021 |
| Metric | NAZ | SGMT |
|---|---|---|
| Price | $12.80 | $7.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.13 |
| AVG Volume (30 Days) | 18.6K | ★ 886.5K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.40 | $3.44 |
| 52 Week High | $13.00 | $11.41 |
| Indicator | NAZ | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 52.93 |
| Support Level | $11.72 | $7.09 |
| Resistance Level | $12.94 | $7.86 |
| Average True Range (ATR) | 0.16 | 0.41 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 57.88 | 52.70 |
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.